Neurostimulation therapy for epilepsy: Current modalities and future directions

Aaron A. Cohen-Gadol, Jeffrey W. Britton, Nicholas M. Wetjen, W. Richard Marsh, Fredric B. Meyer, Corey Raffel

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Neurostimulation is a recent development in the treatment of epilepsy. Vagus nerve stimulation (VNS), the only approved neurostimulation therapy for epilepsy to date, has proved to be a viable adjunctive treatment option. The exact mechanism of action of VNS is not fully understood. In 2 randomized double-blind trials, seizure frequency declined approximately 30% after 3 months of treatment. Long-term follow-up studies suggest that response improves over time, with approximately 35% of patients experiencing a 50% reduction and 20% experiencing a 75% reduction in seizure frequency after 18 months of treatment. Unfortunately, the number of patients rendered medication-free and seizure-free with VNS is low. Vagus nerve stimulation is best viewed as an option for patients who are not surgical candidates or who hesitate to take the risk of surgery yet continue to have seizures despite maximal medical therapy. Stimulation of other regions of the central nervous system for treating epilepsy, including the anterior and centromedian nuclei of the thalamus, the hippocampus, the subthalamic nucleus, and the cerebral neocortex, is currently under investigation. We review the history, proposed mechanisms of action, clinical trials, adverse effects, and future direction of VNS and other modalities of neurostimulation therapy for epilepsy.

Original languageEnglish (US)
Pages (from-to)238-248
Number of pages11
JournalMayo Clinic Proceedings
Volume78
Issue number2
StatePublished - Feb 1 2003

Fingerprint

Vagus Nerve Stimulation
Epilepsy
Seizures
Therapeutics
Anterior Thalamic Nuclei
Intralaminar Thalamic Nuclei
Subthalamic Nucleus
Neocortex
Direction compound
Hippocampus
Central Nervous System
History
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cohen-Gadol, A. A., Britton, J. W., Wetjen, N. M., Richard Marsh, W., Meyer, F. B., & Raffel, C. (2003). Neurostimulation therapy for epilepsy: Current modalities and future directions. Mayo Clinic Proceedings, 78(2), 238-248.

Neurostimulation therapy for epilepsy : Current modalities and future directions. / Cohen-Gadol, Aaron A.; Britton, Jeffrey W.; Wetjen, Nicholas M.; Richard Marsh, W.; Meyer, Fredric B.; Raffel, Corey.

In: Mayo Clinic Proceedings, Vol. 78, No. 2, 01.02.2003, p. 238-248.

Research output: Contribution to journalArticle

Cohen-Gadol, AA, Britton, JW, Wetjen, NM, Richard Marsh, W, Meyer, FB & Raffel, C 2003, 'Neurostimulation therapy for epilepsy: Current modalities and future directions', Mayo Clinic Proceedings, vol. 78, no. 2, pp. 238-248.
Cohen-Gadol AA, Britton JW, Wetjen NM, Richard Marsh W, Meyer FB, Raffel C. Neurostimulation therapy for epilepsy: Current modalities and future directions. Mayo Clinic Proceedings. 2003 Feb 1;78(2):238-248.
Cohen-Gadol, Aaron A. ; Britton, Jeffrey W. ; Wetjen, Nicholas M. ; Richard Marsh, W. ; Meyer, Fredric B. ; Raffel, Corey. / Neurostimulation therapy for epilepsy : Current modalities and future directions. In: Mayo Clinic Proceedings. 2003 ; Vol. 78, No. 2. pp. 238-248.
@article{c4fb6f2e266a4c3d9b72726b43086bc9,
title = "Neurostimulation therapy for epilepsy: Current modalities and future directions",
abstract = "Neurostimulation is a recent development in the treatment of epilepsy. Vagus nerve stimulation (VNS), the only approved neurostimulation therapy for epilepsy to date, has proved to be a viable adjunctive treatment option. The exact mechanism of action of VNS is not fully understood. In 2 randomized double-blind trials, seizure frequency declined approximately 30{\%} after 3 months of treatment. Long-term follow-up studies suggest that response improves over time, with approximately 35{\%} of patients experiencing a 50{\%} reduction and 20{\%} experiencing a 75{\%} reduction in seizure frequency after 18 months of treatment. Unfortunately, the number of patients rendered medication-free and seizure-free with VNS is low. Vagus nerve stimulation is best viewed as an option for patients who are not surgical candidates or who hesitate to take the risk of surgery yet continue to have seizures despite maximal medical therapy. Stimulation of other regions of the central nervous system for treating epilepsy, including the anterior and centromedian nuclei of the thalamus, the hippocampus, the subthalamic nucleus, and the cerebral neocortex, is currently under investigation. We review the history, proposed mechanisms of action, clinical trials, adverse effects, and future direction of VNS and other modalities of neurostimulation therapy for epilepsy.",
author = "Cohen-Gadol, {Aaron A.} and Britton, {Jeffrey W.} and Wetjen, {Nicholas M.} and {Richard Marsh}, W. and Meyer, {Fredric B.} and Corey Raffel",
year = "2003",
month = "2",
day = "1",
language = "English (US)",
volume = "78",
pages = "238--248",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Neurostimulation therapy for epilepsy

T2 - Current modalities and future directions

AU - Cohen-Gadol, Aaron A.

AU - Britton, Jeffrey W.

AU - Wetjen, Nicholas M.

AU - Richard Marsh, W.

AU - Meyer, Fredric B.

AU - Raffel, Corey

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Neurostimulation is a recent development in the treatment of epilepsy. Vagus nerve stimulation (VNS), the only approved neurostimulation therapy for epilepsy to date, has proved to be a viable adjunctive treatment option. The exact mechanism of action of VNS is not fully understood. In 2 randomized double-blind trials, seizure frequency declined approximately 30% after 3 months of treatment. Long-term follow-up studies suggest that response improves over time, with approximately 35% of patients experiencing a 50% reduction and 20% experiencing a 75% reduction in seizure frequency after 18 months of treatment. Unfortunately, the number of patients rendered medication-free and seizure-free with VNS is low. Vagus nerve stimulation is best viewed as an option for patients who are not surgical candidates or who hesitate to take the risk of surgery yet continue to have seizures despite maximal medical therapy. Stimulation of other regions of the central nervous system for treating epilepsy, including the anterior and centromedian nuclei of the thalamus, the hippocampus, the subthalamic nucleus, and the cerebral neocortex, is currently under investigation. We review the history, proposed mechanisms of action, clinical trials, adverse effects, and future direction of VNS and other modalities of neurostimulation therapy for epilepsy.

AB - Neurostimulation is a recent development in the treatment of epilepsy. Vagus nerve stimulation (VNS), the only approved neurostimulation therapy for epilepsy to date, has proved to be a viable adjunctive treatment option. The exact mechanism of action of VNS is not fully understood. In 2 randomized double-blind trials, seizure frequency declined approximately 30% after 3 months of treatment. Long-term follow-up studies suggest that response improves over time, with approximately 35% of patients experiencing a 50% reduction and 20% experiencing a 75% reduction in seizure frequency after 18 months of treatment. Unfortunately, the number of patients rendered medication-free and seizure-free with VNS is low. Vagus nerve stimulation is best viewed as an option for patients who are not surgical candidates or who hesitate to take the risk of surgery yet continue to have seizures despite maximal medical therapy. Stimulation of other regions of the central nervous system for treating epilepsy, including the anterior and centromedian nuclei of the thalamus, the hippocampus, the subthalamic nucleus, and the cerebral neocortex, is currently under investigation. We review the history, proposed mechanisms of action, clinical trials, adverse effects, and future direction of VNS and other modalities of neurostimulation therapy for epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=0037311684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037311684&partnerID=8YFLogxK

M3 - Article

C2 - 12583536

AN - SCOPUS:0037311684

VL - 78

SP - 238

EP - 248

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -